Clinical Factors Associated with Weight Gain in French-Canadian Children and Adolescents Treated With Second Generation Antipsychotics: A 24-Month Retrospective Study
CURRENT RESEARCH IN DIABETES & OBESITY JOURNAL JUNIPER PUBLISHERS Authored by Leila Ben Amor Abstract Objective: To describe clinical factors associated with SGA-induced weight gain induced by long-term second generation antipsychotic (SGA) treatment in children and adolescents. Methods: A 24-month retrospective study conducted between November 2005 and June 2013. 147 antipsychotic-naive patients were selected [mean age 12.8; (95% CI 9.8 to 15.9)] and treated with an SGA (risperidone, olanzapine, quetiapine and aripiprazole) for up to 24 months. Weight and height were measured and BMI (body mass index) z-scores were calculated at baseline, 1, 3, 6, 12 and 24 months. Linear mixed-model analysis was used to compare weight, BMI and BMI z-score changes of the SGA treatment with the repeated factor being the time relative to baseline at 1, 3, 6, 12 and 24 months. Results: After 24 months of SGA treatment, mean weight increased significantly by 12.8 kg (95% CI 10